MedPath

University Of Medicine And Dentistry Of New Jersey

University Of Medicine And Dentistry Of New Jersey logo
🇺🇸United States
Ownership
-
Established
1970-01-01
Employees
-
Market Cap
-
Website
http://www.umdnj.edu/

Combination Medications vs. Patch Alone for Medically-Ill Smokers

Phase 4
Completed
Conditions
Smoking Cessation
Interventions
First Posted Date
2008-10-10
Last Posted Date
2008-10-10
Lead Sponsor
University of Medicine and Dentistry of New Jersey
Target Recruit Count
127
Registration Number
NCT00770666
Locations
🇺🇸

Umdnj-Rwjms, New Brunswick, New Jersey, United States

Internet Use Among Women With Recurrent Metastatic Breast Cancer

Not Applicable
Completed
Conditions
Breast Cancer
First Posted Date
2008-10-09
Last Posted Date
2011-01-31
Lead Sponsor
University of Medicine and Dentistry of New Jersey
Target Recruit Count
70
Registration Number
NCT00770055
Locations
🇺🇸

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer

Phase 1
Terminated
Conditions
Breast Cancer
Interventions
First Posted Date
2008-10-03
Last Posted Date
2023-08-09
Lead Sponsor
University of Medicine and Dentistry of New Jersey
Target Recruit Count
6
Registration Number
NCT00765765
Locations
🇺🇸

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

🇺🇸

Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey, United States

Radiation Therapy Using Gold Markers in Treating Women With Early-Stage Breast Cancer

Phase 1
Completed
Conditions
Breast Cancer
First Posted Date
2008-09-09
Last Posted Date
2012-06-14
Lead Sponsor
University of Medicine and Dentistry of New Jersey
Target Recruit Count
34
Registration Number
NCT00749437
Locations
🇺🇸

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer

Phase 1
Terminated
Conditions
Lung Cancer
Interventions
First Posted Date
2008-08-06
Last Posted Date
2017-05-23
Lead Sponsor
University of Medicine and Dentistry of New Jersey
Target Recruit Count
8
Registration Number
NCT00728845
Locations
🇺🇸

Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey, United States

🇺🇸

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction

Phase 2
Completed
Conditions
Systemic Sclerosis
Interventions
First Posted Date
2008-06-30
Last Posted Date
2008-06-30
Lead Sponsor
University of Medicine and Dentistry of New Jersey
Target Recruit Count
120
Registration Number
NCT00707187
Locations
🇺🇸

UMDNJ, New Brunswick, New Jersey, United States

Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma

Phase 3
Completed
Conditions
Systemic Sclerosis
Interventions
First Posted Date
2008-06-25
Last Posted Date
2008-06-25
Lead Sponsor
University of Medicine and Dentistry of New Jersey
Target Recruit Count
231
Registration Number
NCT00704665

Effects of Sevoflurane and Propofol on Light Flash Evoked Pupillometry

Completed
Conditions
Measurement of Pupil Diameter
First Posted Date
2008-06-12
Last Posted Date
2014-12-19
Lead Sponsor
University of Medicine and Dentistry of New Jersey
Target Recruit Count
30
Registration Number
NCT00695890
Locations
🇺🇸

UMDNJ, Newark, New Jersey, United States

Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

Phase 1
Completed
Conditions
Breast Cancer
Colorectal Cancer
Head and Neck Cancer
Lung Cancer
Melanoma (Skin)
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Unspecified Adult Solid Tumor, Protocol Specific
First Posted Date
2008-04-28
Last Posted Date
2011-05-10
Lead Sponsor
University of Medicine and Dentistry of New Jersey
Target Recruit Count
16
Registration Number
NCT00667641
Locations
🇺🇸

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

Phase 1
Terminated
Conditions
Melanoma (Skin)
First Posted Date
2008-04-28
Last Posted Date
2009-12-11
Lead Sponsor
University of Medicine and Dentistry of New Jersey
Target Recruit Count
15
Registration Number
NCT00667901
Locations
🇺🇸

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath